Cargando…
Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19
At present, a variety of vaccines have been approved, and existing antiviral drugs are being tested to find an effective treatment for coronavirus disease 2019 (COVID-19). However, no standardized treatment has yet been approved by the World Health Organization. The virally encoded chymotrypsin-like...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359926/ https://www.ncbi.nlm.nih.gov/pubmed/35985974 http://dx.doi.org/10.1016/j.joim.2022.08.001 |
_version_ | 1784764239264612352 |
---|---|
author | Yang, Fan Jiang, Xiao-lan Tariq, Akash Sadia, Sehrish Ahmed, Zeeshan Sardans, Jordi Aleem, Muhammad Ullah, Riaz Bussmann, Rainer W. |
author_facet | Yang, Fan Jiang, Xiao-lan Tariq, Akash Sadia, Sehrish Ahmed, Zeeshan Sardans, Jordi Aleem, Muhammad Ullah, Riaz Bussmann, Rainer W. |
author_sort | Yang, Fan |
collection | PubMed |
description | At present, a variety of vaccines have been approved, and existing antiviral drugs are being tested to find an effective treatment for coronavirus disease 2019 (COVID-19). However, no standardized treatment has yet been approved by the World Health Organization. The virally encoded chymotrypsin-like protease (3CL(pro)) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which facilitates the replication of SARS-CoV in the host cells, is one potential pharmacological target for the development of anti-SARS drugs. Online search engines, such as Web of Science, Google Scholar, Scopus and PubMed, were used to retrieve data on the traditional uses of medicinal plants and their inhibitory effects against the SARS-CoV 3CL(pro). Various pure compounds, including polyphenols, terpenoids, chalcones, alkaloids, biflavonoids, flavanones, anthraquinones and glycosides, have shown potent inhibition of SARS-CoV-2 3CL(pro) activity with 50% inhibitory concentration (IC(50)) values ranging from 2–44 µg/mL. Interestingly, most of these active compounds, including xanthoangelol E (isolated from Angelica keiskei), dieckol 1 (isolated from Ecklonia cava), amentoflavone (isolated from Torreya nucifera), celastrol, pristimerin, tingenone and iguesterin (isolated from Tripterygium regelii), tannic acid (isolated from Camellia sinensis), and theaflavin-3,3′-digallate, 3-isotheaflav1in-3 gallate and dihydrotanshinone I (isolated from Salvia miltiorrhiza), had IC(50) values of less than 15 µg/mL. Kinetic mechanistic studies of several active compounds revealed that their mode of inhibition was dose-dependent and competitive, with K(i) values ranging from 2.4–43.8 μmol/L. Given the significance of plant-based compounds and the many promising results obtained, there is still need to explore the phytochemical and mechanistic potentials of plants and their products. These medicinal plants could serve as an effective inexpensive nutraceutical for the general public to help manage COVID-19. |
format | Online Article Text |
id | pubmed-9359926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93599262022-08-09 Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19 Yang, Fan Jiang, Xiao-lan Tariq, Akash Sadia, Sehrish Ahmed, Zeeshan Sardans, Jordi Aleem, Muhammad Ullah, Riaz Bussmann, Rainer W. J Integr Med Review At present, a variety of vaccines have been approved, and existing antiviral drugs are being tested to find an effective treatment for coronavirus disease 2019 (COVID-19). However, no standardized treatment has yet been approved by the World Health Organization. The virally encoded chymotrypsin-like protease (3CL(pro)) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which facilitates the replication of SARS-CoV in the host cells, is one potential pharmacological target for the development of anti-SARS drugs. Online search engines, such as Web of Science, Google Scholar, Scopus and PubMed, were used to retrieve data on the traditional uses of medicinal plants and their inhibitory effects against the SARS-CoV 3CL(pro). Various pure compounds, including polyphenols, terpenoids, chalcones, alkaloids, biflavonoids, flavanones, anthraquinones and glycosides, have shown potent inhibition of SARS-CoV-2 3CL(pro) activity with 50% inhibitory concentration (IC(50)) values ranging from 2–44 µg/mL. Interestingly, most of these active compounds, including xanthoangelol E (isolated from Angelica keiskei), dieckol 1 (isolated from Ecklonia cava), amentoflavone (isolated from Torreya nucifera), celastrol, pristimerin, tingenone and iguesterin (isolated from Tripterygium regelii), tannic acid (isolated from Camellia sinensis), and theaflavin-3,3′-digallate, 3-isotheaflav1in-3 gallate and dihydrotanshinone I (isolated from Salvia miltiorrhiza), had IC(50) values of less than 15 µg/mL. Kinetic mechanistic studies of several active compounds revealed that their mode of inhibition was dose-dependent and competitive, with K(i) values ranging from 2.4–43.8 μmol/L. Given the significance of plant-based compounds and the many promising results obtained, there is still need to explore the phytochemical and mechanistic potentials of plants and their products. These medicinal plants could serve as an effective inexpensive nutraceutical for the general public to help manage COVID-19. Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. 2022-11 2022-08-09 /pmc/articles/PMC9359926/ /pubmed/35985974 http://dx.doi.org/10.1016/j.joim.2022.08.001 Text en © 2022 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Yang, Fan Jiang, Xiao-lan Tariq, Akash Sadia, Sehrish Ahmed, Zeeshan Sardans, Jordi Aleem, Muhammad Ullah, Riaz Bussmann, Rainer W. Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19 |
title | Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19 |
title_full | Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19 |
title_fullStr | Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19 |
title_full_unstemmed | Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19 |
title_short | Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19 |
title_sort | potential medicinal plants involved in inhibiting 3cl(pro) activity: a practical alternate approach to combating covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359926/ https://www.ncbi.nlm.nih.gov/pubmed/35985974 http://dx.doi.org/10.1016/j.joim.2022.08.001 |
work_keys_str_mv | AT yangfan potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT jiangxiaolan potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT tariqakash potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT sadiasehrish potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT ahmedzeeshan potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT sardansjordi potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT aleemmuhammad potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT ullahriaz potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 AT bussmannrainerw potentialmedicinalplantsinvolvedininhibiting3clproactivityapracticalalternateapproachtocombatingcovid19 |